HCA Healthcare Reports Fourth Quarter 2023 Results and Provides 2024 Guidance
- None.
- None.
Insights
The reported financial outcomes from HCA Healthcare, such as revenue growth from $15.497 billion in Q4 2022 to $17.303 billion in Q4 2023 and the increase in Adjusted EBITDA from $3.179 billion to $3.618 billion year-over-year, indicate a robust financial position. The growth in same facility admissions and equivalent admissions suggests a positive trend in patient volumes, which is a critical driver of revenue for healthcare providers. However, the decrease in net income year-over-year, from $2.081 billion to $1.607 billion, may raise concerns among investors about the company's profitability and the factors contributing to this decline.
The share repurchase program announcement of up to $6 billion could be perceived as a signal of confidence in the company's future performance from management, potentially leading to a positive market reaction. However, it's important to consider the opportunity costs of such a program, as these funds could alternatively be used for investments in growth or debt reduction.
The provision of 2024 guidance offers investors a glimpse into the company's expectations for the future, which includes a projected increase in revenues and Adjusted EBITDA. This forward-looking information is crucial for investors to assess the company's growth trajectory and potential investment risks.
The increase in same facility admissions and outpatient surgeries reflects a growing demand for healthcare services, which is likely tied to HCA's diversified portfolio and its ability to meet patient needs. The reported 6.9 percent increase in same facility revenue per equivalent admission suggests effective revenue management and possibly an improved payor mix or pricing strategy.
HCA's capital expenditures of $1.159 billion, excluding acquisitions, demonstrate a commitment to maintaining and expanding facilities, which is essential for long-term growth in the healthcare sector. These investments are likely to improve service offerings and patient care capabilities, which could lead to increased market share and competitive advantage.
The dividend declaration provides a direct benefit to shareholders and reflects the company's financial health and ability to generate cash. However, investors should consider the sustainability of such dividends in the context of the company's overall capital allocation strategy, including its significant share repurchase program and high level of debt.
Considering the broader healthcare industry, HCA's performance, particularly the increase in patient volumes and revenue per admission, is indicative of the sector's resilience amidst economic fluctuations. The company's financial results may influence the perception of the healthcare sector's stability and growth potential among investors.
The guidance provided for 2024, with an anticipated increase in revenue and adjusted EBITDA, suggests optimism about the healthcare market's conditions, despite potential economic headwinds such as inflation. This optimism might be based on expectations of continued demand for healthcare services and the company's strategic initiatives to enhance operational efficiency.
Investors should consider HCA's financial results and guidance in the context of industry benchmarks and macroeconomic factors. The company's performance relative to peers can provide insights into its competitive positioning and potential market share gains or losses.
Bill Rutherford to Retire and Mike Marks to Become CFO
Key fourth quarter metrics (all percentage changes compare 4Q 2023 to 4Q 2022 unless otherwise noted):
-
Revenues totaled
$17.30 3 billion -
Net income attributable to HCA Healthcare, Inc. totaled
$1.60 7 billion$5.93 -
Adjusted EBITDA totaled
$3.61 8 billion -
Cash flows from operating activities totaled
$2.67 4 billion - Same facility admissions increased 3.1 percent while same facility equivalent admissions increased 3.9 percent
“In the quarter, we experienced strong demand for services across our diversified portfolio of markets, facilities, and service lines. This growth coupled with improved cost trends drove solid financial performance in the fourth quarter. Once again, our people have delivered positive outcomes for our patients, the communities we serve, and our other stakeholders. I want to thank them for their hard work and everything they do for our company,” said Sam Hazen, Chief Executive Officer of HCA Healthcare.
Revenues in the fourth quarter of 2023 totaled
For the fourth quarter of 2023, Adjusted EBITDA totaled
Year Ended December 31, 2023
Revenues for the year ended December 31, 2023 totaled
For 2023, Adjusted EBITDA totaled
Balance Sheet and Cash Flows from Operations
As of December 31, 2023, HCA Healthcare, Inc.’s balance sheet reflected cash and cash equivalents of
During the fourth quarter of 2023, the Company repurchased 3.647 million shares of its common stock at a cost of
Share Repurchase Program
The HCA Healthcare, Inc. Board of Directors has authorized an additional share repurchase program for up to
Dividend
HCA today announced that its Board of Directors declared a quarterly cash dividend of
The declaration and payment of any future dividend will be subject to the discretion of the Board of Directors and will depend on a variety of factors, including the Company’s financial condition, results of operations, and contractual restrictions. Future dividends are expected to be funded by cash balances and future cash flows from operations.
2024 Guidance
Today, the Company issued the following estimated guidance for 2024:
|
2024 Guidance Range |
|
Revenues |
|
|
Net Income Attributable to HCA Healthcare, Inc. |
|
|
Adjusted EBITDA |
|
|
EPS (diluted) |
|
|
Capital expenditures for 2024, excluding acquisitions, are estimated to be in the range of
The Company’s 2024 guidance contains a number of assumptions, including, among others, the Company’s current expectations regarding patient volumes and payor mix as well as general economic conditions, including inflation, and excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets.
Adjusted EBITDA is a non-GAAP financial measure. A table reconciling forecasted net income attributable to HCA Healthcare, Inc. to forecasted Adjusted EBITDA is included in this release.
The Company’s guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks, including those set forth below in the Company’s “Forward-Looking Statements.”
CFO Announcement
HCA Healthcare is also announcing today that Bill Rutherford has decided to retire as Executive Vice President and Chief Financial Officer (“CFO”) after a 34-year career with the company. Mike Marks, HCA Healthcare’s current Senior Vice President, Finance, will succeed Mr. Rutherford as Executive Vice President and CFO, effective May 1, 2024.
“Bill has announced his plan to retire from HCA after 34 years with the company,” said Sam Hazen, Chief Executive Officer of HCA Healthcare. “Bill has had a tremendous impact during his ten years as CFO. The impressive operating results and shareholder returns achieved throughout his tenure are a testament to his leadership and disciplined approach to driving profitable growth. Without question, Bill’s legacy will endure.”
“Bill has also developed an incredibly high-performing finance team, including Mike, who is an accomplished finance professional and respected leader. I am thrilled for Mike to take on the CFO role and couldn’t be more confident in his ability to continue to advance our company’s success,” said Hazen. “I want to thank Bill for his many contributions to HCA and congratulate him on his upcoming retirement. I also want to welcome Mike as the new CFO,” said Hazen. “Mike has worked closely with Bill, the senior team, and myself. He will be an exceptional CFO as we continue to deliver on our commitment to the care and improvement of human life while keeping our financial foundation strong.”
Mr. Marks joined HCA Healthcare in 1996 and has held a number of positions in accounting and finance, including Senior Vice President — Finance, Vice President — Financial Operations Support, CFO of the National Group and CFO of the West Florida Division.
Annual Stockholders’ Meeting
The Company’s 2024 annual stockholders’ meeting will be held virtually on April 25, 2024 at 2:00 p.m. Central Time for stockholders of record as of February 26, 2024.
Earnings Conference Call
HCA Healthcare will host a conference call for investors at 9:00 a.m. Central Time today. All interested investors are invited to access a live audio broadcast of the call via webcast. The broadcast also will be available on a replay basis beginning this afternoon. The webcast can be accessed through the Company’s Investor Relations web page at https://investor.hcahealthcare.com/events-and-presentations/default.aspx.
About the Company
As of December 31, 2023, HCA operated 186 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 20 states and the
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include the Company’s financial guidance for the year ending December 31, 2024, as well as other statements that do not relate solely to historical or current facts. Forward-looking statements can be identified by the use of words like “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “initiative” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) changes in or related to general economic conditions nationally and regionally in our markets, including inflation and economic and business conditions (and the impact thereof on the economy, financial markets and banking industry); changes in revenues due to declining patient volumes; changes in payer mix (including increases in uninsured and underinsured patients); potential increased expenses related to labor, supply chain or other expenditures; workforce disruptions; supply shortages and disruptions (including as a result of geopolitical disruptions); and the impact of potential federal government shutdowns, (2) the impact of our significant indebtedness and the ability to refinance such indebtedness on acceptable terms, (3) the impact of current and future federal and state health reform initiatives and possible changes to other federal, state or local laws and regulations affecting the health care industry, including, but not limited to, proposals to expand coverage of federally-funded insurance programs as an alternative to private insurance or establish a single-payer system (such reforms often referred to as “Medicare for All”), (4) the effects related to the implementation of sequestration spending reductions required under the Budget Control Act of 2011, related legislation extending these reductions and those required under the Pay-As-You-Go Act of 2010 as a result of the federal budget deficit impact of the American Rescue Plan Act of 2021, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (5) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (6) the ability to achieve operating and financial targets, attain expected levels of patient volumes and revenues, and control the costs of providing services, (7) possible changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs or Medicaid waiver programs, that may impact reimbursements to health care providers and insurers and the size of the uninsured or underinsured population, (8) personnel-related capacity constraints, increases in wages and the ability to attract, utilize and retain qualified management and other personnel, including affiliated physicians, nurses and medical and technical support personnel, (9) the highly competitive nature of the health care business, (10) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under third-party payer agreements, the ability to enter into and renew third-party payer provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (11) the efforts of health insurers, health care providers, large employer groups and others to contain health care costs, (12) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (13) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (14) changes in accounting practices, (15) the emergence of and effects related to pandemics, epidemics and outbreaks of infectious diseases or other public health crises, including but not limited to developments related to COVID-19, (16) future divestitures which may result in charges and possible impairments of long-lived assets, (17) changes in business strategy or development plans, (18) delays in receiving payments for services provided, (19) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (20) the impact of known and unknown government investigations, litigation and other claims that may be made against us, (21) the impact of actual and potential cybersecurity incidents or security breaches, including the data security incident disclosed in July 2023, (22) our ongoing ability to demonstrate meaningful use of certified electronic health record technology and the impact of interoperability requirements, (23) the impact of natural disasters, such as hurricanes and floods, physical risks from climate change or similar events beyond our control, (24) changes in
| HCA Healthcare, Inc. | |||||||||||
| Condensed Consolidated Comprehensive Income Statements | |||||||||||
| Fourth Quarter | |||||||||||
| Unaudited | |||||||||||
| (Dollars in millions, except per share amounts) | |||||||||||
2023 |
2022 |
||||||||||
Amount |
Ratio |
Amount |
Ratio |
||||||||
| Revenues |
|
|
100.0 |
|
% |
|
|
100.0 |
|
% |
|
| Salaries and benefits | 7,570 |
|
43.7 |
|
7,055 |
|
45.5 |
|
|||
| Supplies | 2,584 |
|
14.9 |
|
2,429 |
|
15.7 |
|
|||
| Other operating expenses | 3,559 |
|
20.7 |
|
2,850 |
|
18.4 |
|
|||
| Equity in earnings of affiliates | (28 |
) |
(0.2 |
) |
(16 |
) |
(0.1 |
) |
|||
| Depreciation and amortization | 789 |
|
4.5 |
|
750 |
|
4.9 |
|
|||
| Interest expense | 491 |
|
2.8 |
|
453 |
|
2.9 |
|
|||
| Gains on sales of facilities | (7 |
) |
- |
|
(1,326 |
) |
(8.6 |
) |
|||
14,958 |
|
86.4 |
|
12,195 |
|
78.7 |
|
||||
| Income before income taxes | 2,345 |
|
13.6 |
|
3,302 |
|
21.3 |
|
|||
| Provision for income taxes | 484 |
|
2.8 |
|
656 |
|
4.2 |
|
|||
| Net income | 1,861 |
|
10.8 |
|
2,646 |
|
17.1 |
|
|||
| Net income attributable to noncontrolling interests | 254 |
|
1.5 |
|
565 |
|
3.7 |
|
|||
| Net income attributable to HCA Healthcare, Inc. |
|
|
9.3 |
|
|
|
13.4 |
|
|||
| Diluted earnings per share |
|
|
|
|
|||||||
| Shares used in computing diluted earnings per share (millions) | 271.186 |
|
285.663 |
|
|||||||
| Comprehensive income attributable to HCA Healthcare, Inc. |
|
|
|
|
|||||||
| HCA Healthcare, Inc. | |||||||||||
| Condensed Consolidated Comprehensive Income Statements | |||||||||||
| For the Years Ended December 31, 2023 and 2022 | |||||||||||
| Unaudited | |||||||||||
| (Dollars in millions, except per share amounts) | |||||||||||
2023 |
2022 |
||||||||||
Amount |
Ratio |
Amount |
Ratio |
||||||||
| Revenues |
|
|
100.0 |
% |
|
|
100.0 |
|
% |
||
| Salaries and benefits | 29,487 |
|
45.4 |
27,685 |
|
46.0 |
|
||||
| Supplies | 9,902 |
|
15.2 |
9,371 |
|
15.6 |
|
||||
| Other operating expenses | 12,875 |
|
19.8 |
11,155 |
|
18.5 |
|
||||
| Equity in earnings of affiliates | (22 |
) |
- |
(45 |
) |
(0.1 |
) |
||||
| Depreciation and amortization | 3,077 |
|
4.7 |
2,969 |
|
5.0 |
|
||||
| Interest expense | 1,938 |
|
3.0 |
1,741 |
|
2.9 |
|
||||
| Losses (gains) on sales of facilities | 5 |
|
- |
(1,301 |
) |
(2.2 |
) |
||||
| Losses on retirement of debt | - |
|
- |
78 |
|
0.1 |
|
||||
57,262 |
|
88.1 |
51,653 |
|
85.8 |
|
|||||
| Income before income taxes | 7,706 |
|
11.9 |
8,580 |
|
14.2 |
|
||||
| Provision for income taxes | 1,615 |
|
2.5 |
1,746 |
|
2.9 |
|
||||
| Net income | 6,091 |
|
9.4 |
6,834 |
|
11.3 |
|
||||
| Net income attributable to noncontrolling interests | 849 |
|
1.3 |
1,191 |
|
1.9 |
|
||||
| Net income attributable to HCA Healthcare, Inc. |
|
|
8.1 |
|
|
9.4 |
|
||||
| Diluted earnings per share |
|
|
|
|
|||||||
| Shares used in computing diluted earnings per share (millions) | 276.412 |
|
294.666 |
|
|||||||
| Comprehensive income attributable to HCA Healthcare, Inc. |
|
|
|
|
|||||||
| HCA Healthcare, Inc. | |||||||||
| Condensed Consolidated Balance Sheets | |||||||||
| Unaudited | |||||||||
| (Dollars in millions) | |||||||||
| December 31, | September 30, | December 31, | |||||||
2023 |
2023 |
2022 |
|||||||
| ASSETS | |||||||||
| Current assets: | |||||||||
| Cash and cash equivalents |
|
|
|
|
|
|
|||
| Accounts receivable | 9,958 |
|
9,182 |
|
8,891 |
|
|||
| Inventories | 2,021 |
|
2,030 |
|
2,068 |
|
|||
| Other | 2,013 |
|
2,191 |
|
1,776 |
|
|||
14,927 |
|
14,294 |
|
13,643 |
|
||||
| Property and equipment, at cost | 58,548 |
|
57,772 |
|
54,757 |
|
|||
| Accumulated depreciation | (30,833 |
) |
(30,655 |
) |
(29,182 |
) |
|||
27,715 |
|
27,117 |
|
25,575 |
|
||||
| Investments of insurance subsidiaries | 477 |
|
382 |
|
381 |
|
|||
| Investments in and advances to affiliates | 756 |
|
739 |
|
823 |
|
|||
| Goodwill and other intangible assets | 9,945 |
|
9,778 |
|
9,653 |
|
|||
| Right-of-use operating lease assets | 2,207 |
|
2,079 |
|
2,065 |
|
|||
| Other | 184 |
|
200 |
|
298 |
|
|||
|
|
|
|
|
|
||||
| LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | |||||||||
| Current liabilities: | |||||||||
| Accounts payable |
|
|
|
|
|
|
|||
| Accrued salaries | 2,127 |
|
1,912 |
|
1,712 |
|
|||
| Other accrued expenses | 3,871 |
|
3,803 |
|
3,581 |
|
|||
| Long-term debt due within one year | 2,424 |
|
2,553 |
|
370 |
|
|||
12,655 |
|
12,407 |
|
9,902 |
|
||||
| Long-term debt, less debt issuance costs and discounts of |
37,169 |
|
36,793 |
|
37,714 |
|
|||
| Professional liability risks | 1,557 |
|
1,590 |
|
1,528 |
|
|||
| Right-of-use operating lease obligations | 1,903 |
|
1,776 |
|
1,752 |
|
|||
| Income taxes and other liabilities | 1,867 |
|
1,666 |
|
1,615 |
|
|||
| Stockholders' equity (deficit): | |||||||||
| Stockholders' deficit attributable to HCA Healthcare, Inc. | (1,774 |
) |
(2,477 |
) |
(2,767 |
) |
|||
| Noncontrolling interests | 2,834 |
|
2,834 |
|
2,694 |
|
|||
1,060 |
|
357 |
|
(73 |
) |
||||
|
|
|
|
|
|
||||
| HCA Healthcare, Inc. | ||||||
| Condensed Consolidated Statements of Cash Flows | ||||||
| For the Years Ended December 31, 2023 and 2022 | ||||||
| Unaudited | ||||||
| (Dollars in millions) | ||||||
2023 |
2022 |
|||||
| Cash flows from operating activities: | ||||||
| Net income |
|
|
|
|
||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||
| Increase (decrease) in cash from operating assets and liabilities: | ||||||
| Accounts receivable | (935 |
) |
(797 |
) |
||
| Inventories and other assets | (126 |
) |
(59 |
) |
||
| Accounts payable and accrued expenses | 604 |
|
(296 |
) |
||
| Depreciation and amortization | 3,077 |
|
2,969 |
|
||
| Income taxes | 229 |
|
571 |
|
||
| Losses (gains) on sales of facilities | 5 |
|
(1,301 |
) |
||
| Losses on retirement of debt | - |
|
78 |
|
||
| Amortization of debt issuance costs and discounts | 35 |
|
29 |
|
||
| Share-based compensation | 262 |
|
341 |
|
||
| Other | 189 |
|
153 |
|
||
| Net cash provided by operating activities | 9,431 |
|
8,522 |
|
||
| Cash flows from investing activities: | ||||||
| Purchase of property and equipment | (4,744 |
) |
(4,395 |
) |
||
| Acquisition of hospitals and health care entities | (635 |
) |
(224 |
) |
||
| Sales of hospitals and health care entities | 193 |
|
1,237 |
|
||
| Change in investments | (112 |
) |
14 |
|
||
| Other | (19 |
) |
(21 |
) |
||
| Net cash used in investing activities | (5,317 |
) |
(3,389 |
) |
||
| Cash flows from financing activities: | ||||||
| Issuances of long-term debt | 3,224 |
|
5,997 |
|
||
| Net change in revolving credit facilities | (1,020 |
) |
120 |
|
||
| Repayment of long-term debt | (909 |
) |
(2,830 |
) |
||
| Distributions to noncontrolling interests | (640 |
) |
(1,025 |
) |
||
| Payment of debt issuance costs | (31 |
) |
(53 |
) |
||
| Payment of dividends | (661 |
) |
(653 |
) |
||
| Repurchase of common stock | (3,811 |
) |
(7,000 |
) |
||
| Other | (246 |
) |
(212 |
) |
||
| Net cash used in financing activities | (4,094 |
) |
(5,656 |
) |
||
| Effect of exchange rate changes on cash and cash equivalents | 7 |
|
(20 |
) |
||
| Change in cash and cash equivalents | 27 |
|
(543 |
) |
||
| Cash and cash equivalents at beginning of period | 908 |
|
1,451 |
|
||
| Cash and cash equivalents at end of period |
|
|
|
|
||
| Interest payments |
|
|
|
|
||
| Income tax payments, net |
|
|
|
|
||
| HCA Healthcare, Inc. | ||||||||||||||||
| Operating Statistics | ||||||||||||||||
| For the Years | ||||||||||||||||
| Fourth Quarter | Ended December 31, | |||||||||||||||
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|||||
| Operations: | ||||||||||||||||
| Number of Hospitals |
|
186 |
|
|
182 |
|
|
186 |
|
|
182 |
|
||||
| Number of Freestanding Outpatient Surgery Centers* |
|
124 |
|
|
126 |
|
|
124 |
|
|
126 |
|
||||
| Licensed Beds at End of Period |
|
49,588 |
|
|
49,281 |
|
|
49,588 |
|
|
49,281 |
|
||||
| Weighted Average Beds in Service |
|
42,072 |
|
|
42,119 |
|
|
41,873 |
|
|
41,982 |
|
||||
| Reported: | ||||||||||||||||
| Admissions |
|
544,554 |
|
|
530,298 |
|
|
2,130,728 |
|
|
2,075,459 |
|
||||
| % Change |
|
2.7 |
% |
|
2.7 |
% |
||||||||||
| Equivalent Admissions |
|
974,561 |
|
|
931,990 |
|
|
3,788,434 |
|
|
3,611,299 |
|
||||
| % Change |
|
4.6 |
% |
|
4.9 |
% |
||||||||||
| Revenue per Equivalent Admission | $ |
17,755 |
|
$ |
16,628 |
|
$ |
17,149 |
|
$ |
16,679 |
|
||||
| % Change |
|
6.8 |
% |
|
2.8 |
% |
||||||||||
| Inpatient Revenue per Admission | $ |
18,992 |
|
$ |
17,634 |
|
$ |
18,201 |
|
$ |
17,361 |
|
||||
| % Change |
|
7.7 |
% |
|
4.8 |
% |
||||||||||
| Patient Days |
|
2,674,331 |
|
|
2,648,683 |
|
|
10,483,236 |
|
|
10,504,145 |
|
||||
| % Change |
|
1.0 |
% |
|
-0.2 |
% |
||||||||||
| Equivalent Patient Days |
|
4,786,197 |
|
|
4,655,841 |
|
|
18,639,194 |
|
|
18,277,212 |
|
||||
| % Change |
|
2.8 |
% |
|
2.0 |
% |
||||||||||
| Inpatient Surgery Cases |
|
132,417 |
|
|
131,840 |
|
|
528,845 |
|
|
522,151 |
|
||||
| % Change |
|
0.4 |
% |
|
1.3 |
% |
||||||||||
| Outpatient Surgery Cases |
|
270,286 |
|
|
265,610 |
|
|
1,044,415 |
|
|
1,023,239 |
|
||||
| % Change |
|
1.8 |
% |
|
2.1 |
% |
||||||||||
| Emergency Room Visits |
|
2,452,395 |
|
|
2,412,781 |
|
|
9,342,783 |
|
|
8,971,951 |
|
||||
| % Change |
|
1.6 |
% |
|
4.1 |
% |
||||||||||
| Outpatient Revenues as a | ||||||||||||||||
| Percentage of Patient Revenues |
|
38.4 |
% |
|
37.5 |
% |
|
38.3 |
% |
|
37.6 |
% |
||||
| Average Length of Stay (days) |
|
4.911 |
|
|
4.995 |
|
|
4.920 |
|
|
5.061 |
|
||||
| Occupancy** |
|
72.5 |
% |
|
72.0 |
% |
|
72.3 |
% |
|
72.1 |
% |
||||
| Same Facility: | ||||||||||||||||
| Admissions |
|
542,628 |
|
|
526,259 |
|
|
2,127,112 |
|
|
2,059,561 |
|
||||
| % Change |
|
3.1 |
% |
|
3.3 |
% |
||||||||||
| Equivalent Admissions |
|
959,366 |
|
|
923,585 |
|
|
3,750,098 |
|
|
3,577,457 |
|
||||
| % Change |
|
3.9 |
% |
|
4.8 |
% |
||||||||||
| Revenue per Equivalent Admission | $ |
17,672 |
|
$ |
16,533 |
|
$ |
17,080 |
|
$ |
16,637 |
|
||||
| % Change |
|
6.9 |
% |
|
2.7 |
% |
||||||||||
| Inpatient Revenue per Admission | $ |
19,025 |
|
$ |
17,530 |
|
$ |
18,210 |
|
$ |
17,313 |
|
||||
| % Change |
|
8.5 |
% |
|
5.2 |
% |
||||||||||
| Inpatient Surgery Cases |
|
132,056 |
|
|
130,804 |
|
|
528,085 |
|
|
517,898 |
|
||||
| % Change |
|
1.0 |
% |
|
2.0 |
% |
||||||||||
| Outpatient Surgery Cases |
|
263,398 |
|
|
261,685 |
|
|
1,026,639 |
|
|
1,002,076 |
|
||||
| % Change |
|
0.7 |
% |
|
2.5 |
% |
||||||||||
| Emergency Room Visits |
|
2,445,405 |
|
|
2,395,650 |
|
|
9,328,741 |
|
|
8,907,055 |
|
||||
| % Change |
|
2.1 |
% |
|
4.7 |
% |
||||||||||
| * Excludes freestanding endoscopy centers (24 centers at December 31, 2023 and 21 centers at December 31, 2022). | ||||||||||||||||
| ** Reflects the rate of occupancy (patient days and observations) based on weighted average beds in service. | ||||||||||||||||
| HCA Healthcare, Inc. | ||||||||||||
| Supplemental Non-GAAP Disclosures | ||||||||||||
| Operating Results Summary | ||||||||||||
| (Dollars in millions, except per share amounts) | ||||||||||||
| For the Years | ||||||||||||
| Fourth Quarter | Ended December 31, | |||||||||||
2023 |
2022 |
2023 |
2022 |
|||||||||
| Revenues |
|
|
|
|
|
|
|
|
||||
| Net income attributable to HCA Healthcare, Inc. |
|
|
|
|
|
|
|
|
||||
| Losses (gains) on sales of facilities (net of tax) | (9 |
) |
(755 |
) |
12 |
|
(727 |
) |
||||
| Losses on retirement of debt (net of tax) | - |
|
- |
|
- |
|
60 |
|
||||
| Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt (a) | 1,598 |
|
1,326 |
|
5,254 |
|
4,976 |
|
||||
| Depreciation and amortization | 789 |
|
750 |
|
3,077 |
|
2,969 |
|
||||
| Interest expense | 491 |
|
453 |
|
1,938 |
|
1,741 |
|
||||
| Provision for income taxes | 486 |
|
422 |
|
1,608 |
|
1,527 |
|
||||
| Net income attributable to noncontrolling interests (b) | 254 |
|
228 |
|
849 |
|
854 |
|
||||
| Adjusted EBITDA (a) |
|
|
|
|
|
|
|
|
||||
| Adjusted EBITDA margin (a) | 20.9 |
% |
20.5 |
% |
19.6 |
% |
20.0 |
% |
||||
| Diluted earnings per share: | ||||||||||||
| Net income attributable to HCA Healthcare, Inc. |
|
|
|
|
|
|
|
|
||||
| Losses (gains) on sales of facilities | (0.03 |
) |
(2.64 |
) |
0.04 |
|
(2.46 |
) |
||||
| Losses on retirement of debt | - |
|
- |
|
- |
|
0.20 |
|
||||
| Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt (a) |
|
|
|
|
|
|
|
|
||||
| Shares used in computing diluted earnings per share (millions) | 271.186 |
|
285.663 |
|
276.412 |
|
294.666 |
|
||||
| ________________________________________________________ | |
(a) |
Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA should not be considered as measures of financial performance under generally accepted accounting principles ("GAAP"). We believe net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA as the primary measures to review and assess operating performance of its health care facilities and their management teams. |
|
Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and GAAP net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that losses (gains) on sales of facilities and losses on retirement of debt will occur in future periods, but the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies. |
|
Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are not measures of financial performance under GAAP, and should not be considered as alternatives to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are not measurements determined in accordance with GAAP and are susceptible to varying calculations, net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies. |
(b) |
The 2022 amounts are net of noncontrolling interests related to gains on sales of facilities. |
| HCA Healthcare, Inc. | ||||||
| Supplemental Non-GAAP Disclosures | ||||||
| 2024 Operating Results Forecast | ||||||
| (Dollars in millions, except per share amounts) | ||||||
| For the Year Ending | ||||||
| December 31, 2024 | ||||||
| Low | High | |||||
| Revenues |
|
|
||||
| Net income attributable to HCA Healthcare, Inc. (a) |
|
|
||||
| Depreciation and amortization | 3,200 |
3,270 |
||||
| Interest expense | 1,985 |
2,040 |
||||
| Provision for income taxes | 1,615 |
1,740 |
||||
| Net income attributable to noncontrolling interests | 850 |
900 |
||||
| Adjusted EBITDA (a) (b) |
|
|
||||
| Diluted earnings per share: | ||||||
| Net income attributable to HCA Healthcare, Inc. |
|
|
||||
| Shares used in computing diluted earnings per share (millions) | 264.000 |
264.000 |
||||
| The Company's forecasted guidance range is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks. | ||||||
| ________________________________________________________ | |
(a) |
The Company does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs (benefits) and impairments of long-lived assets because the Company does not believe that it can forecast these items with sufficient accuracy. |
|
|
(b) |
Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles ("GAAP"). We believe Adjusted EBITDA is an important measure that supplements discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon Adjusted EBITDA as a primary measure to review and assess operating performance of its health care facilities and their management teams. |
|
|
|
Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA is utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. |
|
|
|
Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130835259/en/
INVESTOR CONTACT:
Frank Morgan
615-344-2688
MEDIA CONTACT:
Harlow Sumerford
615-344-1851
Source: HCA Healthcare
FAQ
What were HCA Healthcare, Inc.'s Q4 2023 revenues?
What was HCA Healthcare, Inc.'s net income for Q4 2023?
What was HCA Healthcare, Inc.'s adjusted EBITDA for Q4 2023?
How much was HCA Healthcare, Inc.'s share repurchase program authorized for?
What was the quarterly cash dividend declared by HCA Healthcare, Inc.?
